This article is more than 5 years old. Information may no longer be current.

New trial to evaluate ranibizumab for treating DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — A phase 2 study evaluating the long-term safety and efficacy of ranibizumab for treating diabetic macular edema has begun enrolling patients, according to a press release from the Juvenile Diabetes Research Foundation, one of the study's co-sponsors.

The READ 2 Study (Ranibizumab for Edema of the mAcula in Diabetes Phase 2 Study) seeks to enroll 126 patients with diabetic macular edema (DME). Investigators will examine the safety, efficacy and dosing of intravitreal Lucentis (ranibizumab, Genentech) alone and in combination with laser photocoagulation, the release said.

The new study builds on the phase 1 READ trial, which found a mean visual acuity increase of 12.3 letters in DME patients at 7 months, according to the release.